<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Everolimus</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Everolimus">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Everolimus</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Everolimus</b> is a medication used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.</p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Everolimus</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Everolimus.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Everolimus.svg.png" data-file-width="512" data-file-height="400" data-file-type="drawing" height="172" width="220"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Everolimus_ball-and-stick.png" tppabs="https://ptable.com/wiki/compounds/I/m/Everolimus_ball-and-stick.png" data-file-width="2000" data-file-height="1418" data-file-type="bitmap" height="156" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td>Everolimus <span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ˌ</span><span>ɛ</span><span>v</span><span>ə</span><span>ˈ</span><span>r</span><span>oʊ</span><span>l</span><span>ə</span><span>m</span><span>ə</span><span>s</span></span>/</span></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Afinitor, Zortress</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td><small>42-<i>O</i>-(2-hydroxyethyl)rapamycin</small>, RAD001</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/everolimus.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/everolimus.html'" tppabs="https://www.drugs.com/monograph/everolimus.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a609032.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a609032.html'" tppabs="https://medlineplus.gov/druginfo/meds/a609032.html" class="external text external">a609032</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Everolimus  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Everolimus'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Everolimus" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Everolimus  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Everolimus'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Everolimus" class="external text external">Everolimus</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Everolimus&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Everolimus&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Everolimus&SearchType=BasicSearch" class="external text external">Everolimus</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-0"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-1"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XE10<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XE10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XE10'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XE10" class="external text external">WHO</a></span>)<span> </span>L04AA18<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L04AA18  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L04AA18'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L04AA18" class="external text external">WHO</a></span>)</li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>~30 hours<span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">Dihydroxy-12-[(2<i>R</i>)-1-[(1<i>S</i>,3<i>R</i>,4<i>R</i>)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=159351-69-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=159351-69-6'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=159351-69-6" class="external text external">159351-69-6</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/6442177  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/6442177'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/6442177" class="external text external">6442177</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB01590  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB01590'" tppabs="https://www.drugbank.ca/drugs/DB01590" class="external text external">DB01590</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.21106307.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.21106307.html'" tppabs="http://www.chemspider.com/Chemical-Structure.21106307.html" class="external text external">21106307</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9HW64Q8G6G  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9HW64Q8G6G'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9HW64Q8G6G" class="external text external">9HW64Q8G6G</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D02714  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D02714'" tppabs="https://www.kegg.jp/entry/D02714" class="external text external">D02714</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1908360  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1908360'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1908360" class="external text external">ChEMBL1908360</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID0040599  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID0040599'" tppabs="https://comptox.epa.gov/dashboard/DTXSID0040599" class="external text external">DTXSID0040599</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.149.896  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.149.896'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.149.896" class="external text external">100.149.896</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>53</sub><span>H</span><sub>83</sub><span>N</span><span>O</span><sub>14</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">958.240</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=OCCO%5BC%40%40H%5D1CC%5BC%40H%5D%28C%5BC%40H%5D1OC%29C%5BC%40%40H%5D%28C%29%5BC%40%40H%5D4CC%28%3DO%29%5BC%40H%5D%28C%29%2FC%3DC%28%5CC%29%5BC%40%40H%5D%28O%29%5BC%40%40H%5D%28OC%29C%28%3DO%29%5BC%40H%5D%28C%29C%5BC%40H%5D%28C%29%5CC%3DC%5CC%3DC%5CC%3DC%28%2FC%29%5BC%40%40H%5D%28OC%29C%5BC%40%40H%5D2CC%5BC%40%40H%5D%28C%29%5BC%40%40%5D%28O%29%28O2%29C%28%3DO%29C%28%3DO%29N3CCCC%5BC%40H%5D3C%28%3DO%29O4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=OCCO%5BC%40%40H%5D1CC%5BC%40H%5D%28C%5BC%40H%5D1OC%29C%5BC%40%40H%5D%28C%29%5BC%40%40H%5D4CC%28%3DO%29%5BC%40H%5D%28C%29%2FC%3DC%28%5CC%29%5BC%40%40H%5D%28O%29%5BC%40%40H%5D%28OC%29C%28%3DO%29%5BC%40H%5D%28C%29C%5BC%40H%5D%28C%29%5CC%3DC%5CC%3DC%5CC%3DC%28%2FC%29%5BC%40%40H%5D%28OC%29C%5BC%40%40H%5D2CC%5BC%40%40H%5D%28C%29%5BC%40%40%5D%28O%29%28O2%29C%28%3DO%29C%28%3DO%29N3CCCC%5BC%40H%5D3C%28%3DO%29O4'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=OCCO%5BC%40%40H%5D1CC%5BC%40H%5D%28C%5BC%40H%5D1OC%29C%5BC%40%40H%5D%28C%29%5BC%40%40H%5D4CC%28%3DO%29%5BC%40H%5D%28C%29%2FC%3DC%28%5CC%29%5BC%40%40H%5D%28O%29%5BC%40%40H%5D%28OC%29C%28%3DO%29%5BC%40H%5D%28C%29C%5BC%40H%5D%28C%29%5CC%3DC%5CC%3DC%5CC%3DC%28%2FC%29%5BC%40%40H%5D%28OC%29C%5BC%40%40H%5D2CC%5BC%40%40H%5D%28C%29%5BC%40%40%5D%28O%29%28O2%29C%28%3DO%29C%28%3DO%29N3CCCC%5BC%40H%5D3C%28%3DO%29O4" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">OCCO[C@@H]1CC[C@H](C[C@H]1OC)C[C@@H](C)[C@@H]4CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N3CCCC[C@H]3C(=O)O4</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:HKVAMNSJSFKALM-GKUWKFKPSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459441923&page2=Everolimus  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459441923&page2=Everolimus'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459441923&page2=Everolimus" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>It is the 40-<i>O</i>-(2-hydroxyethyl) derivative of <a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">sirolimus</a> and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).</p>

<p>It is marketed by Novartis under the trade names <b>Zortress</b> (USA) and <b>Certican</b> (European Union and other countries) in transplantation medicine, and as <b>Afinitor</b> (general tumours) and <b>Votubia</b> (tumours as a result of TSC) in oncology. Everolimus is also available from Biocon, with the brand name <i>Evertor</i>.</p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Everolimus is approved for various conditions:</p>
<ul><li>Advanced kidney cancer (US FDA approved in March 2009)<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li>
<li>Prevention of organ rejection after renal transplant(US FDA April 2010)<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention (US FDA October 2010)<span class="mw-ref" id="cite_ref-Nov2010_5-0"><a href="#cite_note-Nov2010-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></li>
<li>Progressive or metastatic pancreatic neuroendocrine tumors not surgically removable (May 2011)<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></li>
<li>Breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer, in conjunction with <a href="Exemestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Exemestane" title="Exemestane">exemestane</a> (US FDA July 2012)<span class="mw-ref" id="cite_ref-July2012_7-0"><a href="#cite_note-July2012-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></li>
<li>Prevention of organ rejection after liver transplant(Feb 2013)</li>
<li>Progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease (US FDA February 2016).<span class="mw-ref" id="cite_ref-NET-2016_8-0"><a href="#cite_note-NET-2016-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></li>
<li>Tuberous sclerosis complex-associated partial-onset seizures for adult and pediatric patients aged 2 years and older. (US FDA April 2018).<span class="mw-ref" id="cite_ref-NET_-2018_9-0"><a href="#cite_note-NET_-2018-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="UK_National_Health_Service">UK National Health Service</h2></summary>
    

<p>NHS England has been criticised for delays in deciding on a policy for the prescription of everolimus in the treatment of Tuberous Sclerosis. 20 doctors addressed a letter to the board in support of the charity Tuberous Scelerosis Association saying " around 32 patients with critical need, whose doctors believe everolimus treatment is their best or only option, have no hope of access to funding. Most have been waiting many months. Approximately half of these patients are at imminent risk of a catastrophic event (renal bleed or kidney failure) with a high risk of preventable death."<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> In May 2015 it was reported that Luke Henry and Stephanie Rudwick, the parents of a child suffering from Tuberous Sclerosis were trying to sell their home in Brighton to raise £30,000 to pay for treatment for their daughter Bethany who has tumours on her brain, kidneys and liver and suffers from up to 50 epileptic fits a day.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Clinical_trials">Clinical trials</h2></summary>
    
<p><span>As of October</span><span>&nbsp;</span><span>2010</span>, Phase III trials are under way in gastric cancer, hepatocellular carcinoma, and lymphoma.<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> The experimental use of everolimus in refractory chronic graft-versus-host disease was reported in 2012.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p>Interim phase III trial results in 2011 showed that adding Afinitor (everolimus) to <a href="Exemestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Exemestane" title="Exemestane">exemestane</a> therapy against advanced breast cancer can significantly improve progression-free survival compared with exemestane therapy alone.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>

<p>A study published in 2012, shows that everolimus sensitivity varies between patients depending on their tumor genomes.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> A group of patients with advanced metastasic bladder carcinoma (NCT00805129) <span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> treated with everolimus revealed a single patient who had a complete response to everolimus treatment for 26 months. The researchers sequenced the genome of this patient and compared it to different reference genomes and to other patients' genomes. They found that mutations in TSC1 led to a lengthened  duration of response to everolimus and to an increase in the time to cancer recurrence. The mutated TSC1 apparently had made these tumors vulnerable to treatment with everolimus.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism">Mechanism</h2></summary>
    
<p>Compared with the parent compound rapamycin, everolimus is more selective for the mTORC1 protein complex, with little impact on the mTORC2 complex.<span class="mw-ref" id="cite_ref-ArriolaApelo_17-0"><a href="#cite_note-ArriolaApelo-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> This can lead to a hyper-activation of the kinase AKT via inhibition on the mTORC1 negative feedback loop, while not inhibiting the mTORC2 positive feedback to AKT. This AKT elevation can lead to longer survival in some cell types. Thus, everolimus has important effects on cell growth, cell proliferation and cell survival.</p>

<p>Additionally, mTORC2 is believed to play an important role in glucose metabolism and the immune system, suggesting that selective inhibition of mTORC1 by drugs such as everolimus could achieve many of the benefits of rapamycin without the associated glucose intolerance and immunosuppression.<span class="mw-ref" id="cite_ref-ArriolaApelo_17-1"><a href="#cite_note-ArriolaApelo-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>TSC1 and TSC2, the genes involved in tuberous sclerosis, act as tumor suppressor genes by regulating mTORC1 activity. Thus, either the loss or inactivation of one of these genes lead to the activation of mTORC1.<span class="mw-ref" id="cite_ref-novartis.com.au_18-0"><a href="#cite_note-novartis.com.au-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>Everolimus binds to its protein receptor FKBP12, which directly interacts with mTORC1, inhibiting its downstream signaling. As a consequence, mRNAs that code for proteins implicated in the cell cycle and in the glycolysis process are impaired or altered, and tumor growth is inhibited.<span class="mw-ref" id="cite_ref-novartis.com.au_18-1"><a href="#cite_note-novartis.com.au-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_reactions">Adverse reactions</h2></summary>
    
<p>A trial using 10<span>&nbsp;</span>mg/day in patients with NETs of GI or lung origin reported "Everolimus was discontinued for adverse reactions in 29% of patients and dose reduction or delay was required in 70% of everolimus-treated patients. Serious adverse reactions occurred in 42% of everolimus-treated patients and included 3 fatal events (cardiac failure, respiratory failure, and septic shock). The most common adverse reactions (incidence greater than or equal to 30%) were stomatitis, infections, diarrhea, peripheral edema, fatigue and rash. The most common blood  abnormalities found (incidence greater than or equal to 50%) were anemia, hypercholesterolemia, lymphopenia, elevated aspartate transaminase (AST) and fasting hyperglycemia.".<span class="mw-ref" id="cite_ref-NET-2016_8-1"><a href="#cite_note-NET-2016-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Role_in_heart_transplantation">Role in heart transplantation</h2></summary>
    
<p>Everolimus may have a role in heart transplantation, as it has been shown to reduce chronic allograft vasculopathy in such transplants. It also may have a similar role to sirolimus in kidney and other transplants.<span class="mw-ref" id="cite_ref-pmid12944570_19-0"><a href="#cite_note-pmid12944570-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Role_in_liver_transplantation">Role in liver transplantation</h2></summary>
    
<p>Although, sirolimus had generated fears over use of m-TOR inhibitors in liver transplantation recipients, due to possible early hepatic artery thrombosis and graft loss, use of everolimus in the setting of liver transplantation is promising. Jeng et al.,<span class="mw-ref" id="cite_ref-PMID_24767339_20-0"><a href="#cite_note-PMID_24767339-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> in their study of 43 patients, concluded the safety of everolimus in the early phase after living donor liver transplantation. In their study, no hepatic artery thrombosis or wound infection was noted. Also, a possible role of everolimus in reducing the recurrence of hepatocellular carcinoma after liver transplantation was correlated. A target trough level of 3<span>&nbsp;</span>ng/mL at 3 months was shown to be beneficial in recipients with pre-transplant renal dysfunction. In their study, 6 of 9 renal failure patients showed significant recovery of renal function, whereas 3 showed further deterioration, one of whom required hemodialysis.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> Recently published report by <a href="javascript:if(confirm('https://www.researchgate.net/profile/Ashok_Thorat2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.researchgate.net/profile/Ashok_Thorat2'" tppabs="https://www.researchgate.net/profile/Ashok_Thorat2" class="external text external">Thorat</a> et al. showed a positive impact on hepatocellular carcinoma (HCC) when everolimus was used as primary immunosuppression starting as early as first week after living donor liver transplantation (LDLT) surgery.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> In their retrospective and prospective analysis at <a href="javascript:if(confirm('http://www.cmuh.cmu.edu.tw/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cmuh.cmu.edu.tw/'" tppabs="http://www.cmuh.cmu.edu.tw/" class="external text external">China Medical University Hospital in Taiwan</a>, the study cohort (n=66) was  divided in two groups depending upon the postoperative immunosuppression. Group A: HCC patients that received <i>Everolimus + Tacrolimus</i> based immunosuppressive regimen (n=37). Group B: HCC patients that received standard <i>Tacrolimus</i> based immunosuppressive regimen without everolimus (n=29). <small><i>The target trough level for EVR was 3 to 5 ng/ml while for TAC it was 8–10 ng/ml.</i></small> The 1-year, 3-year and 4-year overall survival achieved for Group A patients (Everolimus group) was 94.95%, 86.48% and 86.48%, respectively while for Group B patients it was 82.75%, 68.96%, and 62.06%, respectively (<i>p</i>=0.0217). The first 12-month report of ongoing Everolimus multicenter prospective trial in LDLT (H2307 trial), Jeng LB et al. have shown a 0% recurrence of HCC in everolimus group at 12 months.<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> Jeng LB concluded that an early introduction of everolimus + reduced tacrolimus was non-inferior to standard tacrolimus in terms of efficacy and renal function at 12 months, with HCC recurrence only in tacrolimus control patients.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Use_in_vascular_stents">Use in vascular stents</h2></summary>
    
<p>Everolimus is used in drug-eluting coronary stents as an immunosuppressant to prevent restenosis. Abbott Vascular produce an everolimus-eluting stent (EES) called Xience Alpine. It utilizes the Multi-Link Vision cobalt chromium stent platform and Novartis' everolimus. The product is widely available globally including the US, the European Union, and Asia-Pacific (APAC) countries. Boston Scientific also market EESes, recent offerings being Promus Elite and Synergy.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Use_in_aging">Use in aging</h2></summary>
    
<p>Inhibition of mTOR, the molecular target of everolimus, extends the lifespan of model organisms including mice,<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> and mTOR inhibition has been suggested as an anti-aging therapy. Everolimus was used in a recent clinical trial by Novartis, and short-term treatment was shown to enhance the response to the influenza vaccine in the elderly, possible by reversing immunosenescence.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> Everolimus treatment of mice results in reduced metabolic side effects compared to <a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">sirolimus</a>.<span class="mw-ref" id="cite_ref-ArriolaApelo_17-2"><a href="#cite_note-ArriolaApelo-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Discovery and development of mTOR inhibitors</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-1" class="mw-reference-text"><span><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/everolimus.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/everolimus.html'" tppabs="https://www.drugs.com/pregnancy/everolimus.html" class="external text external">Use During Pregnancy and Breastfeeding</a></span></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite id="CITEREFFormicaLorberFriedmanBia2004" class="citation journal cs1">Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD, Lorber MI (March 2004). "The evolving experience using everolimus in clinical transplantation". <i>Transplantation Proceedings</i>. <b>36</b> (2 Suppl): 495S–499S. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.transproceed.2004.01.015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.transproceed.2004.01.015'" tppabs="https://doi.org/10.1016%2Fj.transproceed.2004.01.015" class="external text external">10.1016/j.transproceed.2004.01.015</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15041395  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15041395'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15041395" class="external text external">15041395</a>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('http://www.novartis.com/newsroom/media-releases/en/2009/1301801.shtml  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.novartis.com/newsroom/media-releases/en/2009/1301801.shtml'" tppabs="http://www.novartis.com/newsroom/media-releases/en/2009/1301801.shtml" class="external text external">"Afinitor approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib"</a> (Press release). Novartis. 30 March 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">6 April</span> 2009</span>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20100425204743/http://www.novartis.com/newsroom/media-releases/en/2010/1406625.shtml  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100425204743/http://www.novartis.com/newsroom/media-releases/en/2010/1406625.shtml'" tppabs="https://web.archive.org/web/20100425204743/http://www.novartis.com/newsroom/media-releases/en/2010/1406625.shtml" class="external text external">"Novartis receives US FDA approval for Zortress (everolimus) to prevent organ rejection in adult kidney transplant recipients"</a> (Press release). Novartis. 22 April 2010. Archived from <a href="javascript:if(confirm('http://www.novartis.com/newsroom/media-releases/en/2010/1406625.shtml  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.novartis.com/newsroom/media-releases/en/2010/1406625.shtml'" tppabs="http://www.novartis.com/newsroom/media-releases/en/2010/1406625.shtml" class="external text external">the original</a> on 25 April 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">26 April</span> 2010</span>.</cite></span></li><li id="cite_note-Nov2010-5"> <span id="mw-reference-text-cite_note-Nov2010-5" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://www.genengnews.com/gen-news-highlights/novartis-afinitor-cleared-by-fda-for-treating-sega-tumors-in-tuberous-sclerosis/81244159/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genengnews.com/gen-news-highlights/novartis-afinitor-cleared-by-fda-for-treating-sega-tumors-in-tuberous-sclerosis/81244159/'" tppabs="http://www.genengnews.com/gen-news-highlights/novartis-afinitor-cleared-by-fda-for-treating-sega-tumors-in-tuberous-sclerosis/81244159/" class="external text external">"Novartis' Afinitor Cleared by FDA for Treating SEGA Tumors in Tuberous Sclerosis"</a>. 1 November 2010.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254350.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254350.htm'" tppabs="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254350.htm" class="external free external">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254350.htm</a></span></li><li id="cite_note-July2012-7"> <span id="mw-reference-text-cite_note-July2012-7" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.reuters.com/article/2012/07/20/novartis-afinitor-idUSL2E8IKD8B20120720  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/2012/07/20/novartis-afinitor-idUSL2E8IKD8B20120720'" tppabs="https://www.reuters.com/article/2012/07/20/novartis-afinitor-idUSL2E8IKD8B20120720" class="external text external">"US FDA approves Novartis drug Afinitor for breast cancer"</a>. <i>Reuters</i>. 20 July 2012.</cite></span></li><li id="cite_note-NET-2016-8"> <span id="mw-reference-text-cite_note-NET-2016-8" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488028.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488028.htm'" tppabs="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488028.htm" class="external text external">Everolimus (Afinitor). Feb 2016</a></span></li><li id="cite_note-NET_-2018-9"> <span id="mw-reference-text-cite_note-NET_-2018-9" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604351.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604351.htm'" tppabs="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604351.htm" class="external text external">Everolimus (Afinitor). April 2018</a></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFLintern2015" class="citation news cs1">Lintern, Shaun (14 April 2015). <a href="javascript:if(confirm('http://www.hsj.co.uk/news/policy-delays-risk-preventable-deaths-doctors-warn-nhs-england/5084158.article  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.hsj.co.uk/news/policy-delays-risk-preventable-deaths-doctors-warn-nhs-england/5084158.article#.VTVrEyFVhBd'" tppabs="http://www.hsj.co.uk/news/policy-delays-risk-preventable-deaths-doctors-warn-nhs-england/5084158.article#.VTVrEyFVhBd" class="external text external">"Policy delays risk 'preventable deaths', doctors warn NHS England"</a>. Health Service Journal<span class="reference-accessdate">. Retrieved <span class="nowrap">20 April</span> 2015</span>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://www.express.co.uk/news/uk/576462/Brighton-home-sell-sick-child  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.express.co.uk/news/uk/576462/Brighton-home-sell-sick-child'" tppabs="http://www.express.co.uk/news/uk/576462/Brighton-home-sell-sick-child" class="external text external">"Couple forced to sell home after NHS refuse to fund daughter's treatment for rare illness"</a>. Daily Express. 11 May 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">12 May</span> 2015</span>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><a href="javascript:if(confirm('http://www.genengnews.com/gen-news-highlights/novartis-afinitor-cleared-by-fda-for-treating-sega-tumors-in-tuberous-sclerosis/81244159/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genengnews.com/gen-news-highlights/novartis-afinitor-cleared-by-fda-for-treating-sega-tumors-in-tuberous-sclerosis/81244159/'" tppabs="http://www.genengnews.com/gen-news-highlights/novartis-afinitor-cleared-by-fda-for-treating-sega-tumors-in-tuberous-sclerosis/81244159/" class="external free external">http://www.genengnews.com/gen-news-highlights/novartis-afinitor-cleared-by-fda-for-treating-sega-tumors-in-tuberous-sclerosis/81244159/</a></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFLutzKappGrigoleitStuhler2012" class="citation journal cs1">Lutz M, Kapp M, Grigoleit GU, Stuhler G, Einsele H, Mielke S (April 2012). <a href="javascript:if(confirm('http://www.nature.com/bmt/journal/v47/n1s/pdf/bmt201237a.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nature.com/bmt/journal/v47/n1s/pdf/bmt201237a.pdf'" tppabs="http://www.nature.com/bmt/journal/v47/n1s/pdf/bmt201237a.pdf" class="external text external">"Salvage therapy with everolimus improves quality of life in patients with refractory chronic graft-versus-host disease"</a> <span class="cs1-format">(PDF)</span>. <i>Bone Marrow Transplant</i>. <b>47</b> (S1): S410–S411.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://www.genengnews.com/gen-news-highlights/positive-trial-data-leads-novartis-to-plan-breast-cancer-filing-for-afinitor-by-year-end/81245384/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genengnews.com/gen-news-highlights/positive-trial-data-leads-novartis-to-plan-breast-cancer-filing-for-afinitor-by-year-end/81245384/'" tppabs="http://www.genengnews.com/gen-news-highlights/positive-trial-data-leads-novartis-to-plan-breast-cancer-filing-for-afinitor-by-year-end/81245384/" class="external text external">"Positive Trial Data Leads Novartis to Plan Breast Cancer Filing for Afinitor by Year End"</a>. 2011.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFIyerHanrahanMilowskyAl-Ahmadie2012" class="citation journal cs1">Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB (October 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633467  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633467'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633467" class="external text external">"Genome sequencing identifies a basis for everolimus sensitivity"</a>. <i>Science</i>. <b>338</b> (6104): 221. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.1226344  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.1226344'" tppabs="https://doi.org/10.1126%2Fscience.1226344" class="external text external">10.1126/science.1226344</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633467  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633467'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633467" class="external text external">3633467</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22923433  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22923433'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22923433" class="external text external">22923433</a>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><a href="javascript:if(confirm('http://www.clinicaltrials.gov/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.clinicaltrials.gov/'" tppabs="http://www.clinicaltrials.gov/" class="external autonumber external"></a></span></li><li id="cite_note-ArriolaApelo-17"> <span id="mw-reference-text-cite_note-ArriolaApelo-17" class="mw-reference-text"><cite id="CITEREFArriola_ApeloNeumanBaarSyed2016" class="citation journal cs1">Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, Pumper CP, Kimple ME, Lamming DW (February 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280" class="external text external">"Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system"</a>. <i>Aging Cell</i>. <b>15</b> (1): 28–38. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Facel.12405  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Facel.12405'" tppabs="https://doi.org/10.1111%2Facel.12405" class="external text external">10.1111/acel.12405</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280" class="external text external">4717280</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26463117  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26463117'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26463117" class="external text external">26463117</a>.</cite></span></li><li id="cite_note-novartis.com.au-18"> <span id="mw-reference-text-cite_note-novartis.com.au-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20140308141850/http://www.novartis.com.au/DownloadFile.aspx?t=p&f=afi.pdf&dateid=1343206022000  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140308141850/http://www.novartis.com.au/DownloadFile.aspx?t=p&f=afi.pdf&dateid=1343206022000'" tppabs="https://web.archive.org/web/20140308141850/http://www.novartis.com.au/DownloadFile.aspx?t=p&f=afi.pdf&dateid=1343206022000" class="external text external">"Archived copy"</a>. Archived from <a href="javascript:if(confirm('http://www.novartis.com.au/DownloadFile.aspx?t=p&f=afi.pdf&dateid=1343206022000  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.novartis.com.au/DownloadFile.aspx?t=p&f=afi.pdf&dateid=1343206022000'" tppabs="http://www.novartis.com.au/DownloadFile.aspx?t=p&f=afi.pdf&dateid=1343206022000" class="external text external">the original</a> on 8 March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">26 February</span> 2014</span>.</cite><span class="cs1-maint citation-comment">CS1 maint: archived copy as title (link)</span></span></li><li id="cite_note-pmid12944570-19"> <span id="mw-reference-text-cite_note-pmid12944570-19" class="mw-reference-text"><cite id="CITEREFEisenTuzcuDorentKobashigawa2003" class="citation journal cs1">Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P (August 2003). "Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients". <i>The New England Journal of Medicine</i>. <b>349</b> (9): 847–58. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa022171  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa022171'" tppabs="https://doi.org/10.1056%2FNEJMoa022171" class="external text external">10.1056/NEJMoa022171</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12944570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12944570'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12944570" class="external text external">12944570</a>.</cite></span></li><li id="cite_note-PMID_24767339-20"> <span id="mw-reference-text-cite_note-PMID_24767339-20" class="mw-reference-text"><cite id="CITEREFJengThoratHsiehYang2014" class="citation journal cs1">Jeng LB, Thorat A, Hsieh YW, Yang HR, Yeh CC, Chen TH, Hsu SC, Hsu CH (April 2014). "Experience of using everolimus in the early stage of living donor liver transplantation". <i>Transplantation Proceedings</i>. <b>46</b> (3): 744–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.transproceed.2013.11.068  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.transproceed.2013.11.068'" tppabs="https://doi.org/10.1016%2Fj.transproceed.2013.11.068" class="external text external">10.1016/j.transproceed.2013.11.068</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24767339  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24767339'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24767339" class="external text external">24767339</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text">Jeng L, Thorat A, Yang H, Yeh C-C, Chen T-H, Hsu S-C. Impact of Everolimus On the Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation When Used in Early Stage: A Single Center Prospective Study [abstract]. Am J Transplant. 2015; 15 (suppl 3). <a href="javascript:if(confirm('http://www.atcmeetingabstracts.com/abstract/impact-of-everolimus-on-the-hepatocellular-carcinoma-recurrence-after-living-donor-liver-transplantation-when-used-in-early-stage-a-single-center-prospective-study/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.atcmeetingabstracts.com/abstract/impact-of-everolimus-on-the-hepatocellular-carcinoma-recurrence-after-living-donor-liver-transplantation-when-used-in-early-stage-a-single-center-prospective-study/'" tppabs="http://www.atcmeetingabstracts.com/abstract/impact-of-everolimus-on-the-hepatocellular-carcinoma-recurrence-after-living-donor-liver-transplantation-when-used-in-early-stage-a-single-center-prospective-study/" class="external free external">http://www.atcmeetingabstracts.com/abstract/impact-of-everolimus-on-the-hepatocellular-carcinoma-recurrence-after-living-donor-liver-transplantation-when-used-in-early-stage-a-single-center-prospective-study/</a>. Accessed 1 September 2015.</span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite id="CITEREFThoratJengYangYeh2017" class="citation journal cs1">Thorat A, Jeng LB, Yang HR, Yeh CC, Hsu SC, Chen TH, Poon KS (November 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736740  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736740'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736740" class="external text external">"Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors"</a>. <i>Annals of Hepato-Biliary-Pancreatic Surgery</i>. <b>21</b> (4): 205–211. doi:<a href="javascript:if(confirm('https://doi.org/10.14701%2Fahbps.2017.21.4.205  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.14701%2Fahbps.2017.21.4.205'" tppabs="https://doi.org/10.14701%2Fahbps.2017.21.4.205" class="external text external">10.14701/ahbps.2017.21.4.205</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736740  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736740'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736740" class="external text external">5736740</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29264583  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29264583'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29264583" class="external text external">29264583</a>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite id="CITEREFJengLeeSoinLee2017" class="citation journal cs1">Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, Joo DJ, Uemoto S, Joh J, Yoshizumi T, Yang HR, Song GW, Lopez P, Kochuparampil J, Sips C, Kaneko S, Levy G (December 2017). <a href="javascript:if(confirm('https://ir.ymlib.yonsei.ac.kr/handle/22282913/163311  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ir.ymlib.yonsei.ac.kr/handle/22282913/163311'" tppabs="https://ir.ymlib.yonsei.ac.kr/handle/22282913/163311" class="external text external">"Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study"</a>. <i>American Journal of Transplantation</i>. <b>18</b> (6): 1435–1446. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1111%2Fajt.14623  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fajt.14623'" tppabs="https://doi.org/10.1111%2Fajt.14623" class="external text external">10.1111/ajt.14623</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29237235  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29237235'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29237235" class="external text external">29237235</a>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFHarrisonStrongSharpNelson2009" class="citation journal cs1">Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA (July 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786175'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786175" class="external text external">"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice"</a>. <i>Nature</i>. <b>460</b> (7253): 392–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnature08221  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnature08221'" tppabs="https://doi.org/10.1038%2Fnature08221" class="external text external">10.1038/nature08221</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786175'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786175" class="external text external">2786175</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19587680  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19587680'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19587680" class="external text external">19587680</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFMannickDel_GiudiceLattanziValiante2014" class="citation journal cs1">Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB (December 2014). "mTOR inhibition improves immune function in the elderly". <i>Science Translational Medicine</i>. <b>6</b> (268): 268ra179. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscitranslmed.3009892  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscitranslmed.3009892'" tppabs="https://doi.org/10.1126%2Fscitranslmed.3009892" class="external text external">10.1126/scitranslmed.3009892</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25540326  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25540326'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25540326" class="external text external">25540326</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<ul><li><cite id="CITEREFSedraniCottensKallenSchuler1998" class="citation journal cs1">Sedrani R, Cottens S, Kallen J, Schuler W (August 1998). "Chemical modification of rapamycin: the discovery of SDZ RAD". <i>Transplantation Proceedings</i>. <b>30</b> (5): 2192–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0041-1345%2898%2900587-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0041-1345%2898%2900587-9'" tppabs="https://doi.org/10.1016%2FS0041-1345%2898%2900587-9" class="external text external">10.1016/S0041-1345(98)00587-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9723437  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9723437'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9723437" class="external text external">9723437</a>.</cite></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/everolimus  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/everolimus'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/everolimus" class="external text external">"Everolimus"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="font-size:114%;margin:0 4em">Immunosuppressive drugs<span>&nbsp;</span>/ Immunosuppressants (L04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(initiation)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Antimetabolites</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>purine synthesis inhibitors</i>
<ul><li><a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="Mycophenolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li></ul></li></ul>

<ul><li><i>pyrimidine synthesis inhibitors</i>
<ul><li><a href="Leflunomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li>Teriflunomide</li></ul></li></ul>

<ul><li><i>antifolate</i>
<ul><li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Macrolides/<br>other <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FKBP/Cyclophilin/Calcineurin</i>
<ul><li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li></ul></li></ul>

<ul><li>Abetimus</li>
<li>Gusperimus</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IMiDs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li>Pomalidomide</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li><i>PDE4 inhibitor</i>
<ul><li>Apremilast</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(reception)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL-1 receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">mTOR</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li>Ridaforolimus</li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li>Umirolimus</li>
<li>Zotarolimus</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Extracellular</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">Antibodies</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Monoclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Serum target<br>(noncellular)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Complement component 5</i>
<ul><li>Eculizumab</li></ul></li>
<li><i>TNF</i>
<ul><li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Afelimomab</li>
<li>Certolizumab pegol</li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Nerelimomab</li></ul></li>
<li><i>Interleukin 5</i>
<ul><li>Mepolizumab</li></ul></li>
<li><i>Immunoglobulin E</i>
<ul><li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul></li></ul>

<ul><li><i>Interferon</i>
<ul><li>Faralimomab</li></ul></li></ul>

<ul><li><i>IL-6</i>
<ul><li>Elsilimomab</li></ul></li></ul>

<ul><li><i>IL-12 and IL-23</i>
<ul><li>Lebrikizumab</li>
<li>Ustekinumab</li></ul></li></ul>

<ul><li><i>IL-17A</i>
<ul><li>Secukinumab</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cellular<br>target</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CD3</i>
<ul><li><a href="Muromonab-CD3.htm" tppabs="https://ptable.com/wiki/compounds/A/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li>Otelixizumab</li>
<li>Teplizumab</li>
<li>Visilizumab</li></ul></li>
<li><i>CD4</i>
<ul><li>Clenoliximab</li>
<li>Keliximab</li>
<li>Zanolimumab</li></ul></li>
<li><i>CD11a</i>
<ul><li>Efalizumab</li></ul></li>
<li><i>CD18</i>
<ul><li>Erlizumab</li></ul></li>
<li><i>CD20</i>
<ul><li>Obinutuzumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li>Ocrelizumab</li>
<li>Pascolizumab</li></ul></li>
<li><i>CD23</i>
<ul><li>Gomiliximab</li>
<li>Lumiliximab</li></ul></li>
<li><i>CD40</i>
<ul><li>Teneliximab</li>
<li>Toralizumab</li></ul></li>
<li><i>CD62L/L-selectin</i>
<ul><li>Aselizumab</li></ul></li>
<li><i>CD80</i>
<ul><li>Galiximab</li></ul></li>
<li><i>CD147/Basigin</i>
<ul><li>Gavilimomab</li></ul></li>
<li><i>CD154</i>
<ul><li>Ruplizumab</li></ul></li></ul>

<ul><li><i>BLyS</i>
<ul><li>Belimumab</li>
<li>Blisibimod</li></ul></li>
<li><i>CTLA-4</i>
<ul><li>Ipilimumab</li>
<li>Tremelimumab</li></ul></li>
<li><i>CAT</i>
<ul><li>Bertilimumab</li>
<li>Lerdelimumab</li>
<li>Metelimumab</li></ul></li>
<li><i>Integrin</i>
<ul><li>Natalizumab</li>
<li>Vedolizumab</li></ul></li>
<li><i>Interleukin-6 receptor</i>
<ul><li>Tocilizumab</li></ul></li>
<li><i>LFA-1</i>
<ul><li>Odulimomab</li></ul></li></ul>

<ul><li><i>IL-2 receptor/CD25</i>
<ul><li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Inolimomab</li></ul></li></ul>

<ul><li><i>T-lymphocyte</i> (Zolimomab aritox)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atorolimumab</li>
<li>Cedelizumab</li>
<li>Fontolizumab</li>
<li>Maslimomab</li>
<li>Morolimumab</li>
<li>Pexelizumab</li>
<li>Reslizumab</li>
<li>Rovelizumab</li>
<li>Siplizumab</li>
<li>Talizumab</li>
<li>Telimomab aritox</li>
<li>Vapaliximab</li>
<li>Vepalimomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Polyclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anti-thymocyte globulin</li>
<li>Anti-lymphocyte globulin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">-cept (Fusion)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CTLA-4</i>
<ul><li>Abatacept</li>
<li>Belatacept</li></ul></li>
<li><i>TNF inhibitor</i>
<ul><li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Pegsunercept</li></ul></li>
<li>Aflibercept</li>
<li><a href="Alefacept.htm" tppabs="https://ptable.com/wiki/compounds/A/Alefacept" title="Alefacept">Alefacept</a></li>
<li>Rilonacept</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>






<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-10" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Everolimus&oldid=972225030  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Everolimus&oldid=972225030'" tppabs="https://en.wikipedia.org/wiki/?title=Everolimus&oldid=972225030">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>